Efficacy and Safety of Lansoprazole in Patients with Low to Moderate Bleeding Risk Undergoing Percutaneous Coronary Intervention
Abstract
Abstract Background The routine use of prophylactic proton pump inhibitors (PPIs) in patients with coronary artery disease (CAD) receiving percutaneous coronary intervention (PCI) who are at low to moderate risk of bleeding and who are receiving a combination of aspirin and clopidogrel remains controversial. Aims This study aimed to investigate the gastrointestinal efficacy and cardiovascular safety of PPIs in CAD patients undergoing PCI on dual antiplatelet therapy (DAPT) with low to moderate bleeding risk. Methods In this investigator-initiated, open-label, randomized controlled trial, patients receiving DAPT were assigned to either the lansoprazole group (15 mg once daily) or the control group (no gastrointestinal medication) for an average of 185 days. The primary endpoint was a composite of upper gastrointestinal bleeding (GIB), ulcer-related perforation, or obstruction (ClinicalTrials.gov Identifier: NCT05820048 ; registered on April 6, 2023). Results Of the 300 patients screened, 274 were enrolled and randomized (134 to the lansoprazole group and 140 to the control group). The mean (± s.d.) follow-up duration was 185.0 ± 27.2 days in the lansoprazole group and 186.2 ± 19.0 days in the control group. Two patients (1.5%) in the lansoprazole group experienced GIB events, whereas no events occurred in the control group (P = 0.238; log-rank test, P = 0.150). Conclusions In patients with CAD undergoing PCI and receiving DAPT, prophylactic use of lansoprazole did not…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 300 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.